Pre-made Dupilumab benchmark antibody ( Whole mAb, anti-IL4R therapeutic antibody, Anti-CD124 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-158-1mg	1mg	3090
GMP-Bios-ab-158-10mg	10mg	Inquiry
GMP-Bios-ab-158-100mg	100mg	Inquiry
GMP-Bios-ab-158-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody
INN Name	Dupilumab
Target	IL4R
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi
Conditions Approved	Asthma;Atopic dermatitis;Nasal polyps
Conditions Active	Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria
Conditions Discontinued	Allergic asthma
Development Tech	VelocImmune Mouse